Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

Published on by Global Academic Awards

Dr. Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

University of Rochester | United States

Dr. Richard Moore is a distinguished leader in gynecologic oncology, renowned for his pioneering research, academic excellence, and leadership in translational medicine. He earned degrees in mechanical and industrial engineering before pursuing biology and obtaining his MD from the University of Alberta. His postgraduate training at Eastern Virginia Graduate School of Medicine and fellowship at Brown University established his foundation in women’s oncology. Over his illustrious career, Dr. Richard Moore has held prestigious roles, including Director of the Molecular Therapeutics Laboratory and Center for Biomarkers and Emerging Technology at Brown University, and currently serves as Chief of Gynecologic Oncology and Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers at the University of Rochester Medical Center. A tenured professor, he has contributed significantly to advancing targeted therapeutics, biomarker discovery, and patient-centered oncology care. His work has earned numerous awards, international recognition, and over 8,037 citations from 135 publications and an impressive h-index of 39.

Profile: Scopus

Featured Publications

  • OVARIO Investigators, & Moore, R. G. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: Final analysis and overall survival results from OVARIO. Gynecologic Oncology.

  • NRG Oncology, & Moore, R. G. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine.

  • Moore, R. G., et al. (2025). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

  • Moore, R. G., et al. (2025). Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma. Gynecologic Oncology Reports.

  • Moore, R. G., et al. (2025). Estrogen therapy in patients with gynecologic cancer: A survey of gynecologists and oncologists in the United States. Menopause.

Ashiq Ali | Oncology | Best Researcher Award

Published on by Global Academic Awards

Dr. Ashiq Ali | Oncology | Best Researcher Award

Dr. Ashiq Ali, Shantou University Medical College, China

Dr. Ashiq Ali is a dedicated postdoctoral fellow at Shantou University Medical College, China, with a strong academic background in Pathology and Immunology. He earned his Ph.D. in Pathology and Immunology from the University of Agriculture Faisalabad. With expertise in cancer epigenetics, immunoproteomics, and molecular diagnostics, he has significantly contributed to vaccine development and probiotic research. His commitment to advancing scientific knowledge is evident through numerous publications and successful research projects. As a passionate educator, Dr. Ali has experience mentoring students and conducting lectures on pathology and clinical diagnostics. His dedication to innovative research and academic excellence makes him a valuable contributor to the global scientific community. 📚🔬🧬

Publication Profile

Google Scholar

Education 🎓

Dr. Ashiq Ali pursued his Ph.D. in Pathology and Immunology (2017–2022) from the University of Agriculture Faisalabad, focusing on cancer epigenetics and immunoproteomics. Prior to that, he completed his M.Phil. in Pathology (2014–2016) at the same university, excelling in clinical diagnostics and molecular biology. His academic journey began with a Doctor of Veterinary Medicine (DVM) (2009–2014), where he developed a strong foundation in veterinary pathology, microbiology, and immunology. Throughout his education, Dr. Ali demonstrated exceptional dedication, earning prestigious scholarships and excelling in his research pursuits. His continuous pursuit of knowledge in pathological research and immunological studies highlights his commitment to contributing to the medical and scientific fields. 📘🧑‍🔬🔎

Experience 💼

Dr. Ashiq Ali is currently a postdoctoral fellow at Shantou University Medical College, China, conducting advanced research in pathology and immunology. From 2018 to 2019, he served as a Teaching Assistant at the University of Agriculture Faisalabad, where he conducted practical and theoretical classes on subjects like General Pathology, Clinical Pathology, and Oncology. Between 2016 and 2020, he contributed as a volunteer research assistant, gaining extensive hands-on experience in molecular diagnostics, PCR, immunohistochemistry, and virus cultivation. His role involved supervising laboratory operations, mentoring students, and conducting detailed investigations into infectious diseases, cancer research, and vaccine development. Dr. Ali’s dynamic experience across teaching, research, and lab management highlights his versatility and dedication to scientific advancements. 🧪🔎📊

Awards and Honors 🏆

Dr. Ashiq Ali’s academic excellence has been recognized through prestigious awards, including a Merit Scholarship during his M.Phil. in Pathology at the University of Agriculture Faisalabad (2014–2016). His exceptional research capabilities earned him the Indigenous Ph.D. Fellowship from the Higher Education Commission (HEC) of Pakistan (2018–2022), supporting his groundbreaking work in cancer epigenetics and immunology. These accolades underscore his academic dedication, research competence, and commitment to scientific growth. His contributions have not only elevated his academic standing but also significantly advanced the field of pathology and immunology. 🏅📚🧑‍🔬

Research Focus 🧬

Dr. Ashiq Ali’s research centers on cancer epigenetics, immunoproteomics, and molecular diagnostics, with a keen interest in tumor identification, immunohistochemistry, and gene expression analysis. His expertise includes the development of vaccines using plant-based adjuvants, investigating the therapeutic potential of interferon-alpha against viruses, and applying probiotics for mycotoxin biodegradation. Additionally, Dr. Ali explores the role of pathological markers in disease diagnosis and studies the effects of environmental toxins. His research contributions, particularly in advancing molecular and cellular pathology, continue to pave the way for innovative treatments in infectious diseases, oncology, and veterinary medicine. 🧫🧪🧑‍🔬

Publication Top Notes

  • 📖 Microbial and enzymatic battle with food contaminant zearalenone (ZEN) – Cited by: 23 – Year: 2022

  • 📖 In-vitro assessment of a novel plant rhizobacterium, Citrobacter freundii, for degrading and biocontrol of food mycotoxin deoxynivalenol – Cited by: 21 – Year: 2023

  • 📖 Prevalence, molecular characterization and antibiogram study of Listeria monocytogenes isolated from raw milk and milk products – Cited by: 18 – Year: 2020

  • 📖 Probiotics: Helpful for the prevention of COVID-19? – Cited by: 17 – Year: 2020

  • 📖 Green nanotechnology mediated silver and iron oxide nanoparticles: Potential antimicrobials – Cited by: 15 – Year: 2022

  • 📖 Type I IFNs: a blessing in disguise or partner in crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-induced pathology and potential use of type I IFNs in synergism with IFN-γ – Cited by: 14 – Year: 2021

  • 📖 Potassium use efficiency of maize hybrids – Cited by: 12 – Year: 2012

  • 📖 Aflatoxins associated oxidative stress and immunological alterations are mitigated by dietary supplementation of Pichia kudriavzevii in broiler chicks – Cited by: 10 – Year: 2021

  • 📖 Reply Letter-COVID-19 (Novel Coronavirus 2019)-Recent trends – Cited by: 10 – Year: 2020

  • 📖 Potential therapeutic strategies to combat HCC – Cited by: 9 – Year: 2022

  • 📖 Role of Streptococci as etiological agents of dental caries – Cited by: 9 – Year: 2020

  • 📖 Pollen micromorphology among amaranthaceous species from desert rangeland – Cited by: 8 – Year: 2023

  • 📖 Impact of silver dopant on structural, optical and electrical properties of ZnO nanoparticles – Cited by: 8 – Year: 2019

  • 📖 The adverse effects of carbofuran are efficiently counteracted by the supplementation of star anise (Illicium verum) in broiler chicks – Cited by: 7 – Year: 2020

  • 📖 Mitigative Potential of Novel Lactobacillus plantarum TISTR 2076 against the Aflatoxins-Associated Oxidative Stress and Histopathological Alterations in Liver and Kidney of Broiler Chicks – Cited by: 6 – Year: 2022

Conclusion

Dr. Ashiq Ali’s strong academic background, extensive research experience, and high-impact contributions in pathology and immunology make him a strong candidate for the Best Researcher Award. His expertise in molecular diagnostics, vaccine development, and immunology, coupled with his teaching and mentoring skills, align well with the award’s criteria.

Sharada Mokkapati | Cancer Biology | Best Researcher Award

Published on by Global Academic Awards

Dr. Sharada Mokkapati | Cancer Biology | Best Researcher Award

Dr. Sharada Mokkapati, The UT MD Anderson Cancer Center, United States

Dr. Sharada Mokkapati is an Assistant Professor of Urology (Research) at UT MD Anderson Cancer Center, specializing in oncology, molecular biology, and gene therapy. With a PhD in Genetics from the University of Cologne, Germany (2007), Dr. Mokkapati has contributed significantly to bladder cancer research. She was a key team member in the first FDA-approved gene therapy for bladder cancer and has extensive experience with gene therapy vector development, RNA/DNA molecular techniques, and NextGen sequencing. Her research also includes the identification of miRNA biomarkers and the study of tumor metabolism in gene therapy responses. Dr. Mokkapati has received multiple awards, including the Dodie P. Hawn Fellowship and the Lennox K. Black International prize for excellence in medicine. She is also an adhoc reviewer for journals like BMC Cancer and has co-authored numerous influential publications on bladder cancer and cancer therapy.

Publication Profile

Scopus

Education

Dr. Sharada Mokkapati earned her PhD in Genetics from the University of Cologne, Germany, in February 2007. Her academic journey has focused on genetic research, exploring complex biological systems to understand various genetic disorders. With a robust foundation in genetic principles, she has contributed significantly to the scientific community through research, publications, and collaborations. Dr. Mokkapati’s work has emphasized advancing knowledge in molecular genetics, genetic markers, and hereditary diseases, making a lasting impact on the field. Her dedication continues to inspire the next generation of genetic researchers. 🌱📚

 

Professional Experience 🌟

Dr. Sharada Mokkapati has an extensive career in academia and research. Since 2020, she has served as an Assistant Professor in Urology (Research) at the UT MD Anderson Cancer Center. Previously, she was an Instructor in Urology (Research) at the same institution from 2015 to 2020. Dr. Mokkapati’s academic journey began with a postdoctoral fellowship in the Department of Genetics at UT MD Anderson Cancer Center (2008-2015). Her early career includes graduate studies in Dermatology at the University of Cologne (2002-2007), and research roles at SPIC Science Foundation and Malladi Drugs & Pharmaceuticals in India. 🧬🔬

 

 

Research Achievements 🧬🔬

Dr. Sharada Mokkapati has made significant contributions to the field of oncology and gene therapy. She was a key team member in the development of the first FDA-approved gene therapy for bladder cancer. With extensive experience in oncology, molecular biology, biochemistry, biotechnology, and biomedical research, Dr. Mokkapati has developed and validated vectors for gene therapy. She is highly proficient in RNA, DNA, protein molecular techniques, biochemical assays, and NextGen sequencing. Additionally, Dr. Mokkapati excels in using both xenograft and genetically engineered mouse models for translational biology studies and managing research-related compliance and clinical trial databases. 🧪💡

 

Awards and Honors 🏅🎓

Dr. Sharada Mokkapati has been recognized with several prestigious awards throughout her career. She was honored with the “Dodie P. Hawn Fellowship in Genetics” at UT MD Anderson Cancer Center. Dr. Mokkapati also received the “Travel Award-Lennox K. Black International Prize for Excellence in Medicine” for her contribution to the 12th International Symposium on Basement Membranes in Philadelphia. As a team member, she contributed to the technology transfer for amylase and tannase at SPIC Science Foundation, India. Additionally, she qualified the “National Eligibility Test for Lectureship (NET)” and received the “Dr. T. Ramachandra Rao Memorial Gold Medal” for academic excellence in her Master’s studies. 🏆🧬

 

 

Research Focus 🔬💡

Dr. Sharada Mokkapati’s research primarily focuses on oncology, molecular biology, and gene therapy in the context of bladder cancer. She has contributed extensively to the molecular profiling of bladder cancer, identifying relevant subtypes for biomarker discovery. Her work also includes the development and validation of gene therapy vectors, particularly in non-muscle invasive bladder cancer. Dr. Mokkapati is proficient in RNA/DNA/protein molecular techniques, biochemical analysis, and NextGen sequencing, using mouse models to address both basic biological and translational studies. Her efforts aim to integrate gene therapies into bladder cancer treatment paradigms. 🧬🧫🎯

 

Publication Top Notes

  • Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery (2025) – Cited by 0 🔬📚
  • Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer (2025) – Cited by 0 🧬💡
  • Concomitant antihistamine administration improves survival outcomes in urothelial carcinoma treated with atezolizumab (2025) – Cited by 0 💊📈
  • Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model (2024) – Cited by 0 🧪🧬
  • Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval (2023) – Cited by 7 🏥🔬
  • The current status of gene therapy in bladder cancer (2023) – Cited by 8 📖🔍
  • Lentiviral interferon: A novel method for gene therapy in bladder cancer (2022) – Cited by 8 🧬🧪
  • Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer (2022) – Cited by 16 🧪🔬
  • TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer (2020) – Cited by 7 🧬💥
  • Generation of a novel mouse strain with conditional, cell-type specific, expression of DND1 (2019) – Cited by 2 🐁🔬

 

 

 

Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Published on by Global Academic Awards

Prof. Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Prof. Ammu Kutty Radhakrishnan, Monash University Malaysia, Malaysia

 

Prof. Ammu Kutty Radhakrishnan is a distinguished immunologist with a PhD from the University of Cambridge (1994), an MSc in Biochemistry (1990), and a BSc (First Class Honours) from the University of Malaya (1987). Currently, a Professor of Immunology at Monash University Malaysia, she has over 25 years of academic leadership and research experience. Prof. Ammu specializes in immunotherapy and food as medicine research, serving as Head of this research strength. Her career spans significant roles at International Medical University and Oxford. She is a research consultant, active in COVID-19 vaccine efforts, and supervises PhD and MSc students. 🌿🧬📚

 

Publication Profile

Google Scholar

Academic Excellence

Prof. Ammu Kutty Radhakrishnan has an exceptional academic background, with a PhD in Immunology from the University of Cambridge (1994) and degrees in Biochemistry from the University of Malaya. Her education forms a solid foundation for her expertise in immunology and biomedical sciences, contributing to her distinguished career.

Professional Experience

Prof. Radhakrishnan has held key roles, such as Professor at Monash University Malaysia and the International Medical University (IMU). Her leadership in academic programs, such as head of the Food as Medicine Research Strength and chief examiner roles, showcases her commitment to advancing education and research.

Research Contributions

Prof. Radhakrishnan has supervised numerous PhD and Master’s students, guiding 39 doctoral and 20 master’s research projects to completion. Her extensive research supervision experience highlights her dedication to fostering scientific inquiry and innovation. Additionally, her collaborative efforts with industry partners demonstrate her ability to apply research to real-world problems.

Conclusion

Prof. Ammu Kutty Radhakrishnan’s outstanding academic credentials, extensive research supervision, leadership roles, and global health contributions, she is an ideal candidate for the Best Researcher Award. Her work in immunology, biomedicine, and collaboration with industry partners demonstrates her excellence in both academic and applied research, making her a worthy contender for this prestigious recognition.

 

Publication Top Notes  

  • Protective effect of aqueous extract from Spirulina platensis against cell death induced by free radicals (2010) – 292 citations 🧪
  • Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59 (1994) – 259 citations 🧬
  • Rind of the rambutan, Nephelium lappaceum, a potential source of natural antioxidants (2008) – 193 citations 🍇
  • Current concepts of neurodegenerative mechanisms in Alzheimer’s disease (2018) – 176 citations 🧠
  • Bioactive Compounds: Natural Defense Against Cancer? (2019) – 169 citations 🌿
  • Protective mechanisms of flavonoids in Parkinson’s disease (2015) – 162 citations 🧑‍⚕️
  • Tocotrienol research: past into present (2012) – 157 citations 🌰
  • Standardised Mangifera indica extract is an ideal antioxidant (2009) – 149 citations 🥭
  • Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease (2020) – 128 citations 🚀
  • Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice (2004) – 126 citations 🧫
  • Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity (2013) – 124 citations 🧪

 

Dr Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

Published on by Global Academic Awards

 Gabriel Espinosa Carrasco | Immunotherapy | Best Researcher Award

Dr at Memorial Sloan Kettering Cancer Center,Spain.

Dr. Gabriel Espinosa Carrasco is a distinguished immunologist affiliated with Memorial Sloan Kettering Cancer Center. His research primarily focuses on T cell activation and the mechanisms of self-antigen recognition in immunology. Dr. Espinosa Carrasco’s work advances our understanding of immune responses in various contexts, bridging the gap between basic science and clinical applications.

Profile:

orcid

Education:

  1. Ph.D. in Biological Sciences and Immunology (2011-2016)
    University of Montpellier, INSERM Unit 1183 (France)
    Title: CD8+ and CD4+ T cell activation in response to self-antigens: from the lymphoid tissue to the target organ.
  2. Master in Advanced Immunology (2010-2011)
    University of Barcelona (UB), Barcelona (Spain)
  3. Bachelor’s Degree in Biology (2004-2010)
    Autonomous University of Barcelona (UAB), Barcelona (Spain)

Research Experience:

  1. Post-doctoral Scholar (2022-now)
    Cancer Virotherapy and Immunotherapy Group, Bellvitge Institute for Biomedical Research (IDIBELL)
    Department: Molecular Mechanisms and Experimental Therapy in Oncology
    Supervisor: Dr. Ramon Alemany
    🌟 Focus: Investigating novel virotherapy and immunotherapy approaches for cancer treatment.
  2. Post-doctoral Research Scholar (2017-2022)
    Memorial Sloan-Kettering Cancer Center, Immunology Program, New York
    Project: Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
    Supervisor: Dr. Andrea Schietinger
    🔬 Focus: Enhancing the effectiveness of immunotherapies in solid tumors.
  3. Ph.D. Student (2011-2016)
    INSERM Unit 1183, Montpellier
    Projects:
    a) Study the cooperation of effector CD8+ and CD4+ T cells in pancreas infiltration and beta cell destruction in real-time.
    b) Role of bacterial product translocation in the breakdown of CD8+ T cell peripheral tolerance under lymphopenic conditions.
    Supervisor: Dr. Javier Hernández
    📚 Focus: Understanding T cell interactions and their role in autoimmune responses.
  4. Master Internship (2010-2011)
    Institute of Biotechnology and Biomedicine, Barcelona
    Analysis of peptides directory associated with HLA class I molecules from human thymus and spleen.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Peptide analysis and immune recognition.
  5. Bachelor’s Internship (2008-2009)
    Institute of Biotechnology and Biomedicine, Barcelona
    Composition analysis of the HLA-DR-associated human thymus peptidome.
    Supervisor: Dr. Iñaki Alvarez
    🔬 Focus: Immune system peptide composition.

Research Interests:

Dr. Espinosa Carrasco’s research primarily focuses on T cell activation, self-antigen recognition, and the development of new therapeutic strategies for autoimmune diseases and cancer immunotherapy. His work aims to elucidate the complex interactions within the immune system to enhance treatment efficacy

Awards and Honors:

  • 2024: Provisionally selected for the “Best Researcher Award 2024” (ACA awards)
  • 2022: Selected Speaker, Recent insights into Immuno-Oncology, Leuven, Belgium
  • 2021-2022: Grant recipient, Ludwig Center Basic and Translational Immunology Postdoctoral RFA Memorial Sloan Kettering Cancer Center, New York, USA. $100,000/year
  • 2019: Third prize poster presentation award, Tumor Microenvironments: Mechanisms and Therapeutic Implication 6th Annual Symposium, New York, USA
  • 2017: Invited seminar speaker, Georgetown University, Department of Microbiology and Immunology
  • 2016: Excelente Cum Laude Tesis Doctoral, University of Montpellier, Montpellier, France
  • 2015: Best poster presentation award, Institute for Regenerative Medicine and Biotherapy Annual Retreat, Montpellier, France
  • 2014: Travel Grant, European Association for the Study of Diabetes conference
  • 2012-2015: Research grant from the French Ministry of Research (MRT scholarship), €21,000/year
  • 2009-2010: ERASMUS scholarship from the Autonomous University of Barcelona (UAB), University of Nancy

Publications:

  • Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell, 2024. Link.
  • TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med, 2022. Link.
  • Fate bifurcation of beta cell-specific CD8 T cells drives type 1 diabetes. Nature, 2022. Link.
  • Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci USA, 2019. Link.
  • Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas. Frontiers in Immunology, 2018. Link.
  • CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas. Frontiers in Immunology, 2018. Link.
  • Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell interplay. Theranostics, 2018. Link.
  • PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis. Annals of the Rheumatic Diseases, 2016. Link.
  • Metabolism Regulates Exposure of Pancreatic Islets to Circulating Molecules In Vivo. Diabetes, 2016. Link.
  • Systemic LPS Translocation Activates Cross-Presenting Dendritic Cells but Is Dispensable for the Breakdown of CD8+ T Cell Peripheral Tolerance in Irradiated Mice. PLoS One, 2015. Link.